EP0538459A4 - Phospholipid-targeted thrombolytic agents - Google Patents

Phospholipid-targeted thrombolytic agents

Info

Publication number
EP0538459A4
EP0538459A4 EP19920913004 EP92913004A EP0538459A4 EP 0538459 A4 EP0538459 A4 EP 0538459A4 EP 19920913004 EP19920913004 EP 19920913004 EP 92913004 A EP92913004 A EP 92913004A EP 0538459 A4 EP0538459 A4 EP 0538459A4
Authority
EP
European Patent Office
Prior art keywords
phospholipid
thrombolytic agents
targeted
targeted thrombolytic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920913004
Other languages
English (en)
Other versions
EP0538459A1 (de
Inventor
Jonathan Tait
Kazuo Fujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP0538459A1 publication Critical patent/EP0538459A1/de
Publication of EP0538459A4 publication Critical patent/EP0538459A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP19920913004 1991-05-09 1992-05-11 Phospholipid-targeted thrombolytic agents Ceased EP0538459A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69736491A 1991-05-09 1991-05-09
US697364 1991-05-09

Publications (2)

Publication Number Publication Date
EP0538459A1 EP0538459A1 (de) 1993-04-28
EP0538459A4 true EP0538459A4 (en) 1993-06-16

Family

ID=24800848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920913004 Ceased EP0538459A4 (en) 1991-05-09 1992-05-11 Phospholipid-targeted thrombolytic agents

Country Status (5)

Country Link
EP (1) EP0538459A4 (de)
JP (1) JPH05508664A (de)
CA (1) CA2086437A1 (de)
TW (1) TW239869B (de)
WO (1) WO1992019279A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733066B1 (de) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting verfahren und mitteln
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
CA2180555C (en) * 1994-01-24 2004-12-14 Sudhakar Kasina Radiolabeled annexins
EP1364964A1 (de) * 1994-06-16 2003-11-26 Neorx Corporation Radioaktivmarkierte Annexin-Galaktose Konjugate
WO1995034315A1 (en) * 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
JPH10512852A (ja) * 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
DE69533366T2 (de) * 1994-12-07 2005-08-04 Neorx Corp., Seattle Radioaktivmarkierte annexin-galaktose-cluster konjugate
TW541184B (en) 1997-04-30 2003-07-11 Univ Leland Stanford Junior Use of annexin for imaging cell death in vivo
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
FR2784106B1 (fr) 1998-10-02 2002-04-19 Commissariat Energie Atomique Structure chimique ayant une affinite pour un phospholipide, et compose de marquage, trousse de diagnostic, et medicament comprenant cette structure
ATE359807T1 (de) * 2001-02-21 2007-05-15 Surromed Inc Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
WO2002080754A2 (en) 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
JP2004529922A (ja) 2001-04-03 2004-09-30 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 生体内における細胞死の画像化の方法
FR2841557B1 (fr) * 2002-07-01 2005-12-09 Commissariat Energie Atomique Peptides ayant une affinite pour un phospholipide et utilisations
FR2841558B1 (fr) * 2002-07-01 2004-08-13 Commissariat Energie Atomique Peptides marques ayant une affinite pour un phospholipide et utilisations
FR2856069A1 (fr) * 2003-06-10 2004-12-17 Bionexis Molecules de ciblage et de liberation de composes therapeutiques et leur utilisation
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293567A1 (de) * 1987-03-28 1988-12-07 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vascular-antikoagulierende Proteine, DNA die diese kodieren, Verfahren zu deren Herstellung sowie deren Verwendung
WO1991009953A1 (en) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1992005749A1 (en) * 1990-10-04 1992-04-16 New England Deaconess Hospital Corporation Soluble thrombogenesis inhibitor conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293567A1 (de) * 1987-03-28 1988-12-07 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Vascular-antikoagulierende Proteine, DNA die diese kodieren, Verfahren zu deren Herstellung sowie deren Verwendung
WO1991009953A1 (en) * 1989-12-29 1991-07-11 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
WO1992005749A1 (en) * 1990-10-04 1992-04-16 New England Deaconess Hospital Corporation Soluble thrombogenesis inhibitor conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL CHEMISTRY HOPPE-SEYLER vol. 371, May 1990, BERLIN-NEW YORK pages 383 - 388 R\MISCH J. ET AL. 'Purification and characterization of six annexins from human placenta.' *
See also references of WO9219279A1 *

Also Published As

Publication number Publication date
TW239869B (de) 1995-02-01
CA2086437A1 (en) 1992-11-10
WO1992019279A1 (en) 1992-11-12
JPH05508664A (ja) 1993-12-02
EP0538459A1 (de) 1993-04-28

Similar Documents

Publication Publication Date Title
DE69307690D1 (en) Implantierbare penis-prothese
DE69319731D1 (en) Wässrige polyurethan-dispersionen
AU115931S (en) Cuff-link
GB2267325B (en) Autotensioner
DE59302394D1 (en) Linearlagerelement
DE69306746D1 (en) Schlichtmittelzusammensetzung
DE69329469D1 (en) Fluegelzellenmaschine
EP0563714A3 (en) Tnf-muteins
EP0538459A4 (en) Phospholipid-targeted thrombolytic agents
GB2264893B (en) Workcentre
DE69310500D1 (en) Racemisierungsverfahren
HU9501775D0 (en) Substituted 6-azaandrostenones
HU9501695D0 (en) Substituted benzazepinones
EP0556141A3 (en) Air-filtration-module
AU116869S (en) Bottle-cooler
DE69327712D1 (en) Custardkreme
DE69318966D1 (en) Chemilumineszenzverstärker
DE69321365D1 (en) Polyacetalharzzusammensetzung
DE69315037D1 (en) Phasendifferenz-kompensationsfilm
GB9322576D0 (en) Antihaemostatic agents
ZA937403B (en) Substituted carbamoylpyrazolines
ZA937442B (en) Substituted 2-arylpyrroles
EP0586950A3 (en) Seeddrill
EP0555626A3 (en) Coinchecker
GB2266446B (en) Litterbins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930423

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19950929

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970929